generalized osteoarthritis
Recently Published Documents


TOTAL DOCUMENTS

67
(FIVE YEARS 4)

H-INDEX

19
(FIVE YEARS 0)

Cureus ◽  
2021 ◽  
Author(s):  
Andrew R Medvec ◽  
Sanjeev Shrestha ◽  
Lisa L Schroeder

2021 ◽  
Vol 29 ◽  
pp. S80-S81
Author(s):  
M.S Yau ◽  
H. Jonsson ◽  
J. Lynch ◽  
C.E. Lewis ◽  
J.C. Torner ◽  
...  

Author(s):  
Akpabio Akpabio ◽  
Richard Akintayo ◽  
Abubakar Yerima ◽  
Hakeem Olaosebikan ◽  
Emaediong Akpan-Ekpo ◽  
...  

2021 ◽  
Vol 15 (1) ◽  
pp. 111-118
Author(s):  
I. S. Dydykina ◽  
P. S. Kovalenko ◽  
D. M. Kudinsky

The article discusses the treatment of patients with primary generalized osteoarthritis (OA), a common joint lesion of different localization. Clinical guidelines are presented that provide guidance on various drug and non-drug approaches in the treatment of primary generalized OA. In accordance with the modern understanding of the pathogenesis of OA, the role of inflammation and the influence of various pro-inflammatory factors, the priority of anti-inflammatory therapy, primarily non-steroidal anti-inflammatory drugs (NSAIDs), is justified. A clinical case of a 5-year observation of a patient with primary generalized OA and low compliance to treatment with symptom-modifying slowacting drugs is described. For articular syndrome exacerbations etoricoxib (Kostarox®) was mainly used as an analgesic and anti-inflammatory agent at a dose of 60 mg / day for 7–14 days with a good effect. Due to self-isolation and inability to visit a doctor during COVID-19 pandemic, the patient took etoricoxib for a long time (up to 200 days) for severe neck- and backpain relief, the duration of some courses was up to3 months. We discuss the possibility of etoricoxib use not only in the «on demand» mode, but also for a long time – until the effect is achieved.


2020 ◽  
Vol 50 (2) ◽  
pp. 183-191 ◽  
Author(s):  
E. Kovari ◽  
A. Kaposi ◽  
G. Bekes ◽  
Z. Kiss ◽  
R. Kurucz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document